No.

Publication Date

Citing Article

1

2023

Alia Aldahlawi, Fatemah Basingab, Jehan Alrahimi, Kawther Zaher, Peter Pushparaj, Mohammed Hassan, Kaltoom Al‑sakkaf. Herpesvirus entry mediator as a potential biomarker in breast cancer compared with conventional cytotoxic T‑lymphocyte‑associated antigen 4, Biomedical Reports. 2023; 19: 56.  https://doi.org/10.3892/br.2023.1638

2

2021

Federica Miglietta, Maria Vittoria Dieci, Gaia Griguolo, Valentina Guarneri. Neoadjuvant approach as a platform for treatment personalization: focus on HER2-positive and triple-negative breast cancer, Cancer Treatment Reviews. 2021; 98: 102222102222.  https://doi.org/10.1016/j.ctrv.2021.102222

3

2023

María Luisa Sánchez-León, Carlos Jiménez-Cortegana, Silvia Silva Romeiro, Carmen Garnacho, Luis de la Cruz-Merino, Daniel J. García-Domínguez, Lourdes Hontecillas-Prieto, Víctor Sánchez-Margalet. Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells, International Journal of Molecular Sciences. 2023; 24: 5208.  https://doi.org/10.3390/ijms24065208

4

2023

Sharat Chopra, Muskaan Khosla, Raghavan Vidya. Innovations and Challenges in Breast Cancer Care: A Review, Medicina. 2023; 59: 957.  https://doi.org/10.3390/medicina59050957

5

2024

Anuradha Dnyanmote, Himashree M.P.. Unusual Case of Papillary Carcinoma of the Breast, Cureus. 2024;   https://doi.org/10.7759/cureus.63568

6

2024

Christina Bruss, Veruschka Albert, Stephan Seitz, Stephanie Blaimer, Kerstin Kellner, Fabian Pohl, Olaf Ortmann, Gero Brockhoff, Anja K. Wege. Neoadjuvant radiotherapy in ER+, HER2+, and triple-negative -specific breast cancer based humanized tumor mice enhances anti-PD-L1 treatment efficacy, Frontiers in Immunology. 2024; 15: 1355130.  https://doi.org/10.3389/fimmu.2024.1355130